Ratka-Krüger Petra, Schacher Beate, Bürklin Thomas, Böddinghaus Boris, Holle Rolf, Renggli Heinz H, Eickholz Peter, Kim Ti-Sun
Department of Operative Dentistry and Periodontology, School of Dental Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
J Periodontol. 2005 Jan;76(1):66-74. doi: 10.1902/jop.2005.76.1.66.
Topical application of active substances offers an additional option in periodontal therapy. The aim of this study was to examine the influence of the administration of a novel, biodegradable 14% doxycycline gel on microbiological findings, in connection with scaling and root planing.
One hundred ten patients in three centers (Frankfurt and Heidelberg, Germany; Nijmegen, The Netherlands) with moderate to advanced periodontitis were evaluated in this randomized, double-masked, split-mouth clinical trial. In each patient, three test teeth were randomly assigned to one of three treatment modalities: 1) scaling and root planing (SRP) alone; 2) SRP with subgingival placebo gel (VEH); or 3) SRP and 14% doxycycline gel (DOX). Subgingival plaque samples were analyzed at baseline and 3 and 6 months after therapy for Actinobacillus actinomycetemcomitans (A.a.), Tannerella forsythensis (T.f.), Porphyromonas gingivalis (P.g.), and Treponema denticola (T.d.) using a RNA probe. Samples from 10 patients were tested for resistance against doxycycline, amoxicillin/clavulanic acid, cefoxitin, clindamycin, and metronidazole using agar diffusion testing.
The largest decrease in pathogens was found after 3 months, with the most pronounced differences between DOX and SRP (P <0.05). At 6 months, pathogens were still reduced markedly in all groups. Treatment results were consolidated for VEH and DOX, with a slight deterioration for SRP (DOX versus SRP: P <0.001). Resistance was observed to amoxycillin/clavulanic acid, cefoxitin, clindamycin, and metronidazole (four isolates) but not to doxycycline.
The addition of subgingival instillation of a 14% doxycycline gel resulted in pronounced reduction of periodontal pathogens after 3 months and stabilizing results up to 6 months after therapy. Resistance to doxycycline was not induced.
活性物质的局部应用为牙周治疗提供了另一种选择。本研究的目的是探讨一种新型可生物降解的14%强力霉素凝胶给药对微生物学结果的影响,并与龈下刮治和根面平整联合使用。
在这项随机、双盲、分口临床试验中,对来自三个中心(德国法兰克福和海德堡;荷兰奈梅亨)的110例中度至重度牙周炎患者进行了评估。在每位患者中,三颗测试牙被随机分配到三种治疗方式之一:1)仅龈下刮治和根面平整(SRP);2)龈下刮治和根面平整联合使用龈下安慰剂凝胶(VEH);或3)龈下刮治和根面平整联合使用14%强力霉素凝胶(DOX)。在基线时以及治疗后3个月和6个月,使用RNA探针分析龈下菌斑样本中的伴放线放线杆菌(A.a.)、福赛坦氏菌(T.f.)、牙龈卟啉单胞菌(P.g.)和具核梭杆菌(T.d.)。使用琼脂扩散试验对10例患者的样本进行了对强力霉素、阿莫西林/克拉维酸、头孢西丁、克林霉素和甲硝唑的耐药性测试。
3个月后发现病原体减少最多,DOX组和SRP组之间差异最为显著(P<0.05)。6个月时,所有组的病原体仍显著减少。VEH组和DOX组的治疗结果得到巩固,SRP组略有恶化(DOX组与SRP组:P<0.001)。观察到对阿莫西林/克拉维酸、头孢西丁、克林霉素和甲硝唑(4株分离菌)有耐药性,但对强力霉素无耐药性。
龈下滴注14%强力霉素凝胶可在3个月后显著减少牙周病原体,并在治疗后6个月内使结果稳定。未诱导对强力霉素的耐药性。